The ghrelin receptor GHS-R1a: research background

Ipamorelin and the growth hormone releasing peptides are described as ligands at GHS-R1a, and the receptor is worth understanding for anyone reading that literature: it has an unusual discovery history, distinctive pharmacology, and a second splice variant that complicates interpretation. This note is background on the receptor for researchers, drawn from the published literature. It describes research, not any use of any compound outside the laboratory. All Alphex products are for laboratory and in-vitro research only.

Discovery, in reverse order

Unusually, the ligands came first. Synthetic growth hormone releasing peptides such as GHRP-6 were developed in the 1980s from enkephalin-derived leads and were shown to stimulate growth hormone release, but the receptor they acted on was unknown, and it was clearly not the receptor for growth hormone releasing hormone. The receptor was cloned in 1996 and named the growth hormone secretagogue receptor (GHS-R). Its endogenous ligand was not identified until 1999, when ghrelin, a 28-residue acylated peptide from the stomach, was characterised. So the field had synthetic ligands for roughly fifteen years before it knew what they bound or what the natural signal was.

The receptor

• GHS-R1a is a class A G-protein-coupled receptor, signalling principally through Gq and phospholipase C to mobilise intracellular calcium. It is expressed in the pituitary and hypothalamus and at lower levels in several peripheral tissues.
• GHS-R1b is a truncated splice variant with five transmembrane domains. It does not bind the classical ligands productively and does not signal on its own, but it can heterodimerise with 1a and modulate its trafficking and signalling. Assays that do not distinguish the two, or cell lines expressing both, are a known source of inconsistent results.
• Constitutive activity. GHS-R1a has notably high ligand-independent basal activity, which is relevant to inverse-agonist work and to interpreting baseline in functional assays.
• Ghrelin's acylation. The endogenous ligand requires octanoylation of Ser3 by ghrelin O-acyltransferase for activity; des-acyl ghrelin behaves differently. Synthetic secretagogues do not need this modification, which is one reason they were useful tools.

Why the synthetic ligands differ from each other

GHRP-6, GHRP-2 and Ipamorelin share a pharmacophore of aromatic D-residues and a basic C-terminal lysine, and differ in the substitutions around it. Published characterisation reported differences in potency and in effects on other pituitary axes in the assay systems used, with Ipamorelin designed for selectivity within those systems. Those are findings in defined preclinical assays and should be cited as such rather than generalised. See the three-compound comparison and the Ipamorelin guide.

Practical notes for in-vitro work

• Know which variant your cells express. 1a alone, or 1a plus 1b, changes the readout.
• Calcium mobilisation assays are the standard functional readout; high constitutive activity means baseline matters.
• Peptide handling dominates variability. These peptides are aromatic and adsorb at low concentration; use low-binding plastic and fresh dilutions. See adsorption.
• Controls: vehicle, scrambled peptide, and a reference secretagogue where available. See controls and design.
• Molar units throughout, with net-content correction. See calculating concentration.

Sources and further reading

• Kojima M et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999: identification of the endogenous GHS-R ligand

Alphex supplies Ipamorelin as a laboratory reagent at 99+% HPLC purity. Alphex research peptides are supplied for laboratory and in-vitro research by qualified researchers only. They are not authorised for human or veterinary use.

Research use only. Alphex products are supplied exclusively for laboratory and in-vitro research by qualified researchers. They are not authorised for human or veterinary use, and nothing in this note is advice on any such use.

Published 21 May 2026, last reviewed 16 August 2026. Alphex reviews research notes when the testing method, the catalogue or UK guidance changes.

Alphex Research Team

Alphex Limited, UK research peptide supplier

The Alphex research team writes and maintains these notes for UK laboratories buying research peptides. Every batch Alphex lists is verified by reverse-phase HPLC with a batch-matched Certificate of Analysis. Content covers laboratory and in-vitro research only.